DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

Autres langues Dawnrays Pharmaceutical (Holdings) Limited

Actions

2348

KYG2687M1006

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:17 08/10/2026			Varia. 5j.	Varia. 1 janv.
0,9600 ^HKD	0,00%		-1,54%	-21,31%

28/08	Dawnrays Pharmaceutical (Holdings) Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI
28/08	Dawnrays Pharmaceutical (Holdings) Limited annonce un dividende intérimaire (semestriel) pour le semestre clos le 30 juin 2026, payable le 09 octobre 2026	CI

Autres langues

28/08	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026
28/08	Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026
29/05	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg
22/05	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025
27/03	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025
27/03	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share
27/03	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026
22/08/25	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025
22/08/25	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025
22/08/25	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln
31/07/25	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025
23/05/25	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024
23/05/25	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024
28/03/25	Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
28/03/25	Dawnrays Pharmaceutical Limited Proposes Special Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025
28/03/25	Dawnrays Pharmaceutical Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025
28/03/25	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2024
03/10/24	Dawnrays Pharmaceutical Grants 16 Million Share Options to CEO, Employees
16/09/24	Dawnrays Pharmaceutical Appoints CEO
13/09/24	Dawnrays Pharmaceutical Limited Appoints Yu Liwei as Chief Executive Officer
11/09/24	Dawnrays Pharmaceutical's CEO Resigns
11/09/24	Dawnrays Pharmaceutical Limited Announces Resignation of Wu Weixian as Chief Executive Officer
26/08/24	Dawnrays Pharmaceutical H1 Profit Spikes; Shares Up 3%
23/08/24	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 03 October 2024, Payable on 03 October 2024
23/08/24	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2024